Crossmark

Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy

Published Online: 2022-09-16

Authors

Hermawan, Adam http://orcid.org/0000-0001-5851-3691
Putri, Herwandhani
License Information

Text and Data Mining valid from 2022-09-16

Version of Record valid from 2022-09-16
More Information

Article History

Received: 18 April 2022

Accepted: 6 September 2022

First Online: 16 September 2022

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no conflict of interest.

Document is current